DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Acanya (Benzoyl Peroxide / Clindamycin Phosphate) - Summary

 



ACANYA SUMMARY

ACANYA Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) is a combination product with two active ingredients in an aqueous gel formulation. Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

ACANYA™ Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older.

Important Limitations of Use

The safety and efficacy of the use of this product in the treatment of any other disorders have not been evaluated.


See all indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Acanya (Benzoyl Peroxide / Clindamycin)

Health Tip: What's Triggering My Acne?
Source: MedicineNet Acne Specialty [2009.06.24]
Title: Health Tip: What's Triggering My Acne?
Category: Health News
Created: 6/24/2009 7:00:00 AM
Last Editorial Review: 6/24/2009

New Laser Combo Therapy Zaps Acne
Source: MedicineNet Acne Specialty [2009.03.09]
Title: New Laser Combo Therapy Zaps Acne
Category: Health News
Created: 3/7/2009 2:00:00 AM
Last Editorial Review: 3/9/2009

Acne Cream Not Linked to Raised Death Risk
Source: MedicineNet tretinoin Specialty [2009.01.26]
Title: Acne Cream Not Linked to Raised Death Risk
Category: Health News
Created: 1/24/2009 2:00:00 AM
Last Editorial Review: 1/26/2009

FDA OKs New Acne Gel Epiduo
Source: MedicineNet adapalene Specialty [2009.01.07]
Title: FDA OKs New Acne Gel Epiduo
Category: Health News
Created: 1/7/2009
Last Editorial Review: 1/7/2009

Acne (Pimples)
Source: MedicineNet Boils Specialty [2008.07.16]
Title: Acne (Pimples)
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 7/16/2008

more news >>

Published Studies Related to Acanya (Benzoyl Peroxide / Clindamycin)

Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study. [2009.09]
INTRODUCTION: A solubilized 5% BPO gel has been developed to enhance the bioavailability, follicular penetration, and efficacy of BPO... CONCLUSION: Compared with BPO/clindamycin, the solubilized BPO gel offers significantly greater reductions in non-inflammatory lesion count and comparable reductions in inflammatory lesion count in the absence of an antibiotic.

Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. [2009.08]
BACKGROUND: Oral antibiotics are commonly prescribed for moderate or severe acne, but there may be limitations due to concerns about side effects associated with systemic treatments. OBJECTIVE: To evaluate the efficacy and safety of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BP 2.5%) aqueous gel in the treatment of moderate or severe acne subpopulations... CONCLUSION: Clindamycin-BP 2.5% aqueous gel is an effective and safe once-daily treatment for moderate or severe acne.

A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. [2009.07]
A 3-step acne system has been developed to enhance the bioavailability and follicular penetration of benzoyl peroxide (BPO). Participants with mild to moderate facial acne vulgaris were randomly assigned to 10 weeks' facial treatment with the 3-step acne system (proprietary salicylic acid cleanser 2% twice daily, proprietary salicylic acid toner 2% once daily, and solubilized BPO gel 5% twice daily) or with control cleanser twice daily plus clindamycin 1%-BPO 5% gel (jar formulation) twice daily...

Comparison of 2 clindamycin 1%-benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris. [2009.05]
Combination therapy for the topical treatment of acne vulgaris using benzoyl peroxide (BPO) and an antibiotic is more efficacious and better tolerated than treatment with either component alone... The addition of hydrating excipients in the C/BPO HE formulation appears to improve patient tolerance and acceptance, which will likely help patients to comply with therapy.

Prospective, open-label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. [2009.03]
BACKGROUND: Used as individual agents, topical antibiotics and benzoyl peroxide are known to be effective in treatment of acne. Clindamycin phosphate 1% with benzoyl peroxide 5% (CDP/BPO) is a new combination gel, made by rationale, in that combination drug is more effective than either ingredients used alone. Adapalene 0.1% (ADA) is the third-generation retinoid, shown to be as effective as other topical retinoid with well tolerability. OBJECTIVES: To compare the efficacy and tolerability in combination of CDP/BPO in comparison with ADA in Asian patients with mild to moderate acne vulgaris... CONCLUSION: Combination formulation of CDP/BPO and ADA were shown to be both effective in decreasing total, inflammatory, and non-inflammatory lesion counts along with well tolerability in Asian patients with mild to moderate acne vulgaris.

more studies >>

Clinical Trials Related to Acanya (Benzoyl Peroxide / Clindamycin)

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne [Recruiting]
Multi-center, single-blind, randomized, comparative, split-face study. The duration of the study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin and benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. After visit 3, subjects will commence application of clindamycin and benzoyl peroxide gel to the entire face for an additional 6 weeks.

more trials >>

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009